Routine statin treatment after acute coronary syndromes?

References 

1. Pasternak RC, Grundy SM, Levy D, et al.  27th Bethesda conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. In: J Am Coll Cardiol. 27:1996;p. 978–990
   • Abstract
   • Full-Text PDF (1670 KB)
2. Miller M, Byington R, Hunninghake D, et al.  Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) investigators. Arch Intern Med. 2000;160:343–347
   • MEDLINE
3. European Action on Secondary Prevention by Intervention to Reduce Events (EUROASPIRE I and II group) . Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357:995–1001
   • Abstract
   • Full Text
   • Full-Text PDF (100 KB)
4. Muhlestein J, Horne B, Bair T, et al.  Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol. 2001;87:257–261
   • Abstract
   • Full Text
   • Full-Text PDF (160 KB)
5. Fonarow GC, Gawlinski A, Moughrabi S, et al.  Improved treatment of Coronary Heart disease by implementation of a cardiac hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819–822
   • Abstract
   • Full Text
   • Full-Text PDF (72 KB)
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;28:2486–2497
7. Schwartz GG, Olsson AG, Ezekowitz MD, et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718
   • MEDLINE
8. Arntz H, Agrawal R, Wunderlich W, et al.  Beneficial effects of pravastatin (+/− cholestiramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study). Am J Cardiol. 2000;86:1293–1298
   • Abstract
   • Full Text
   • Full-Text PDF (324 KB)
9. Kayikcioglu M, Turkoglu C, Kultursay H, et al.  The short-term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction [abstract]. Circulation. 2000;102(2 Suppl):303
10. Aronow HD, Topol EJ, Roe MT, et al.  Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063–1068
    • Abstract
    • Full Text
    • Full-Text PDF (101 KB)
11. Stenestrand U, Wallentin L. For the Swedish register of Cardiac Intensive Care (RISKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430–436
    • MEDLINE
12. Collins R, Heart Protection Study (HPS) . Paper presented at: American Heart Association Scientific Sessions; November 11-14. 2001; Anaheim, Calif
13. Ahnve S, Angelin B, Edhag O, et al.  Early determination of serum lipids and apolipoproteins in acute myocardial infarction: possibility for immediate intervention. J Intern Med. 1989;226:297–301
    • MEDLINE
14. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22:933–940
    • Abstract
    • Full-Text PDF (1489 KB)
15. Grundy SM, Balady GJ, Criqui MH, et al.  When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation. 1997;95:1683–1685
    • MEDLINE
16. Birtcher KK, Bowden C, Ballantyne CM, et al.  Strategies for implementing lipid-lowering therapy: pharmacy-based approach. Am J Cardiol. 2000;85:30A–35A
    • MEDLINE
17. LaBresh KA, Owen P, Alteri C, et al.  Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative. Am J Cardiol. 2000;85:23A–29A
    • MEDLINE
18. Dangas G, Badimon JJ, Smith DA, et al.  Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile [see comments]. J Am Coll Cardiol. 1999;33:1294–1304
    • Abstract
    • Full Text
    • Full-Text PDF (294 KB)
19. Notarbartolo A, Davi G, Averna M, et al.  Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247–251
    • MEDLINE
20. Liem A, van Boven AJ, Withagen AP, et al.  Fluvastatin in acute myocardial infarction: effects on early and late ischemia events: the FLORIDA trial [abstract]. Circulation. 2000;102:2672–d
21. Schiele R, Gitt AK, Heer T, et al.  Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: results of MITRA 2 [abstract]. Circulation. 2000;102(2 Suppl):435
22. Hamm CW, Heeschen C, Boehm M, et al.  Role of statins in patients with acute coronary syndromes [abstract]. Circulation. 2000;102(2 Suppl):435
23. Giugliano RP, Antman EM, Thompson SL, et al.  Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality. J Am Coll Cardiol. 2001;37(Suppl):316A
24. Cannon CP, McCabe CH, Bentley J, et al.  Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16 [abstract]. J Am Coll Cardiol. 2001;37(A Suppl):334
    • Full Text
    • Full-Text PDF (130 KB)
25. McGuire DK, Kristinsson A, Bhapkar MV, et al.  Early statin use after acute coronary syndromes (ACS) and outcomes at 90 days [abstract]. Circulation. 2001;104(2 Suppl)):343
26. Anonymous . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
    • Abstract
27. Sacks FM, Pfeffer MA, Moye LA, et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335:1001–1009
    • MEDLINE
28. Smith SC, Blair SN, Bonow RO, et al.  AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577–1579
29. Cooke GE, Bray PF, Hamlington JD, et al.  PlA2 polymorphism and efficacy of aspirin. Lancet. 1998;351:1253
    • Full Text
    • Full-Text PDF (51 KB)
30. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
    • MEDLINE
31. Braunwald E, Antman EM, Beasley JW, et al.  ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. 2000;102:1193–1209
32. Fonarow GC, French WJ, Parsons LS, et al.  Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38–44
33. DeBusk RF, Miller NH, Superko HR, et al.  A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120:721–729
    • MEDLINE